<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617651</url>
  </required_header>
  <id_info>
    <org_study_id>DTC22-IP018</org_study_id>
    <nct_id>NCT05617651</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T</brief_title>
  <official_title>Phase 1 Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T in Healthy Adult Volunteers Under Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the pharmacokinetic and safety of IY-NT-T in healthy adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 study to evaluate the safety and the pharmacokinetics of IY-NT-T in healthy adult&#xD;
      volunteers under fed condition&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2024</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>In order to prevent distortion (bias) affecting test results during sample analysis, this clinical trial shall not be disclosed to analysis manager and analyst until the specimen analysis is completed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ilaprazole AUCt</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>ilaprazole AUCt(Area under the concentration-time curve)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ilaprazole Cmax</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>ilaprazole Cmax(Maximum concentration of drug in plasma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole AUC∞</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>ilaprazole AUC∞(Area under the plasma drug concentration-time curve from time 0 to infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole tmax</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>ilaprazole tmax(Time to maximum plasma concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole t1/2</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>ilaprazole t1/2(Terminal elimination half-life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole tmax-tlag</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>Ilaprazole tmax-tlag (Time to maximum plasma concentration minus Lag time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ilaprazole intra-subject tlag difference</measure>
    <time_frame>Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour</time_frame>
    <description>Ilaprazole intra-subject Lag time difference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 : Ilaprazole 10mg 2Tab, one a day&#xD;
Period 2 : Ilaprazole 20mg 1Tab, one a day&#xD;
Period 3 : Ilaprazole 10mg 2Tab, one a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 : Ilaprazole 20mg 1Tab, one a day&#xD;
Period 2 : Ilaprazole 10mg 2Tab, one a day&#xD;
Period 3 : Ilaprazole 20mg 1Tab, one a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IY-NT-T</intervention_name>
    <description>Ilaprazole 20mg</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IY-NT-R</intervention_name>
    <description>Ilaprazole 10mg</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
    <other_name>Noltec(the brand name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteers aged 19 years and above at screening&#xD;
&#xD;
          2. A volunteer who weighs ≥ 50kg (≥ 45kg for women) and has a body mass index(BMI)* of&#xD;
             ≥18.0 and ≤ 30 at screening&#xD;
&#xD;
             *BMI(body mass index, kg/m^2)= Body weight (kg)/[height (m)^2]&#xD;
&#xD;
          3. A volunteer who has no congenital or chronic diseases, no pathological symptoms, or&#xD;
             findings from medical examination at screening&#xD;
&#xD;
          4. A volunteer who is determined by the principal investigator or&#xD;
             sub-investigator(responsible physician) as eligible as a subject based on diagnostic&#xD;
             tests( hematology, hematochemical, serum, urinalysis) and electrocardiogram tests&#xD;
             established and conducted according to the characteristics of the study drug&#xD;
&#xD;
          5. A volunteer and their spouse or partner, who agree to use a medically appropriate&#xD;
             method of contraception to exclude potential of pregnancy and not to provide sperm or&#xD;
             ova from the first dose to 7 days after the last dose of study drug&#xD;
&#xD;
             * Contraception methods: Intrauterine device, vasectomy, tubal ligation and&#xD;
             contraceptive barrier methods (male condoms, women condoms, cervical caps.&#xD;
             Contraceptive diaphragm, sponge,etc) used in combination or if spermicide is used, two&#xD;
             or more contraceptive barrier methods&#xD;
&#xD;
          6. A volunteer who voluntarily provided written consent to participation in the entire&#xD;
             study process after being fully informed of the study objective, contents,&#xD;
             characteristics of the study drugs, and expected adverse reactions, prior to study&#xD;
             participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A volunteer who has a history or present symptoms of clinically significant disorders&#xD;
             relating to any of the following: digestive system, cardiovascular system, endocrine&#xD;
             system, respiratory system, blood and lymphatic, infectious disease, renal, urinary,&#xD;
             and reproductive, system, nervous system, musculoskeletal system, immune system,&#xD;
             otolaryngology, skin and subcutaneous tissue system, and ophthalmic system&#xD;
&#xD;
          2. A volunteer who has a history of gastrointestinal surgery that may affect drug&#xD;
             absorption (except simple appendectomy or hernia surgery) or has gastrointestinal&#xD;
             diseases&#xD;
&#xD;
          3. A volunteer who has taken drugs that induce or inhibit drug metabolizing enzymes such&#xD;
             as barbiturates within 1 month prior to the first dose or who has taken drugs that may&#xD;
             interfere with clinical study within 10 days prior to the first dose(Provided that,&#xD;
             participation may be considered based on drug-drug interaction, pharmacokinetics and&#xD;
             pharmacodynamics(such as half-life) of study drug)&#xD;
&#xD;
          4. A volunteer who has participated in other clinical trials or bioequivalence studies&#xD;
             within 6 months prior to the first dose of the study drug&#xD;
&#xD;
          5. A volunteer who has participated in whole blood donation within 8 weeks prior to first&#xD;
             dose, or apheresis donation within w weeks prior to first dose, or received blood&#xD;
             donation within 4 weeks prior to first dose.&#xD;
&#xD;
          6. A volunteer that meets any of the following conditions within 1 month prior to first&#xD;
             dose&#xD;
&#xD;
               -  Average alcohol intake(for men): &gt; 21 glass/week&#xD;
&#xD;
               -  Average alcohol intake(for women): &gt; 14 glass/week (1 glass = 50ml of soju or&#xD;
                  30ml of liquor, or 250ml of beer)&#xD;
&#xD;
               -  Average cigarette smoking: &gt; 20 cigarettes per day.&#xD;
&#xD;
          7. A volunteer that meets any of the following categories&#xD;
&#xD;
               -  Volunteer who is hypersensitive to the active ingredient or other ingredients of&#xD;
                  this drug&#xD;
&#xD;
          8. Patients that meet any of the following conditions&#xD;
&#xD;
               -  Gastric ulcer patients possibly related to a malignant tumor&#xD;
&#xD;
               -  Hepatic disorder or renal disorder patients&#xD;
&#xD;
               -  Patients receiving Atazanavir&#xD;
&#xD;
               -  Patients receiving Rilpivirine-containing products&#xD;
&#xD;
          9. A volunteer who is considered by the investigator to be ineligible to participate in&#xD;
             this study for other reasons&#xD;
&#xD;
         10. Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Woo Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung Hwa Hong, bachelor</last_name>
    <phone>+82.2.570.3777</phone>
    <email>jhhong@ilyang.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun Ho Kwon, bachelor</last_name>
    <phone>+82.2.570.3795</phone>
    <email>yhkwon@ilyang.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gwanak-gu</state>
        <zip>08756</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Chae-Woon Jeong, bachelor</last_name>
      <phone>+82.70.4665.9450</phone>
      <email>m3437@newyjh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>February 27, 2023</last_update_submitted>
  <last_update_submitted_qc>February 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>proton pump inhibitor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

